INB-500 iPSC

N/A

Report date: 2023/11/06 14:34:48

Base Information

Drug NameINB-500 iPSC

Drug Alias Nameinduced pluripotent stem cell (iPSC) gamma-delta T cell therapyINB-500 Induced Pluripotent Stem Cell (iPSC) therapyINB-500 iPSC

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionStem cell replacementsT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIN8BIO Inc

China Registration ClassN/A

Develop Information

Active CompaniesIN8BIO Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A